Loading, Please Wait...
CARLSBAD, Calif., July 26, 2019 (GLOBE NEWSWIRE) -- SeaSpine Holdings Corporation (NASDAQ: SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, announced today the implantation of the 20,000th NanoMetalene®interbody device. This milestone exemplifies SeaSpine's mission to develop clinically relevant, cost-effective procedural solutions to treat spinal disorders by providing high-quality, differentiated, and complementary technologies that leverage the Company’s core competencies in orthobiologics, interbody devices, and modular spinal implant systems.
NanoMetalene is a proprietary surface technology for interbody implants that incorporates a sub-micron layer of commercially pure titanium molecularly bonded to a PEEK implant using a high-energy, low-temperature process referred to as atomic fusion deposition. It is designed to provide a bone-friendly titanium surface on endplates and throughout graft apertures, while retaining the benefits associated with traditional PEEK implants, such as biocompatibility, a modulus of elasticity similar to bone, and excellent radiographic visibility for post-operative imaging.
“This milestone reflects the success of our strategy to align NanoMetalene with our comprehensive DBM portfolio and deliver synergistic solutions that maximize clinical value while reducing the need for high-cost orthobiologics,” stated Troy Woolley, Vice President of Marketing, Spinal Implants. “Our ability to develop and deliver procedural solutions that address key clinical needs enables us to differentiate our products with both surgeons and our distributor partners and take share in this competitive market.”
SeaSpine has been successful in its commitment to expand NanoMetalene technology throughout its entire interbody portfolio. With the recent full launch of the Regatta® Lateral System, NanoMetalene is now featured across seven different product families. They include Shoreline® ACS (cervical), Cambria™ (cervical), Hollywood™ (posterior lumbar), Hollywood™ VI (posterior lumbar), Ventura™ (posterior lumbar), Vu aPOD™ Prime (anterior lumbar), and Regatta (lateral lumbar).
SeaSpine (www.seaspine.com) is a global medical technology company focused on the design, development and commercialization of surgical solutions for the treatment of patients suffering from spinal disorders. SeaSpine has a comprehensive portfolio of orthobiologics and spinal implants solutions to meet the varying combinations of products that neurosurgeons and orthopedic spine surgeons need to perform fusion procedures on the lumbar, thoracic and cervical spine. SeaSpine’s orthobiologics products consist of a broad range of advanced and traditional bone graft substitutes that are designed to improve bone fusion rates following a wide range of orthopedic surgeries, including spine, hip, and extremities procedures. SeaSpine’s spinal implants portfolio consists of an extensive line of products to facilitate spinal fusion in degenerative, minimally invasive surgery (MIS), and complex spinal deformity procedures. Expertise in both orthobiologic sciences and spinal implants product development allows SeaSpine to offer its surgeon customers a differentiated portfolio and a complete solution to meet their fusion requirements. SeaSpine currently markets its products in the United States and in approximately 30 countries worldwide through a committed network of increasingly exclusive distribution partners.
SeaSpine cautions you that statements included in this news release that are not a description of historical facts are forward-looking statements that are based on the Company’s current expectations and assumptions. Such forward-looking statements include, but are not limited to, statements relating to: the ability of NanoMetalene surface technology to provide intended benefits; the Company’s strategy to align NanoMetalene with its DBM portfolio and deliver solutions that maximize clinical value while reducing the need for high-cost orthobiologics; the Company’s ability to differentiate its products with both surgeons and distributor partners; and the Company’s ability to take market share. Among the factors that could cause or contribute to material differences between the Company’s actual results and the expectations indicated by the forward-looking statements are risks and uncertainties that include, but are not limited to: the ability of NanoMetalene to perform as designed and intended and to meet the needs of surgeons and patients; the lack of clinical validation for NanoMetalene surface technology and/or to reduce the need for high-cost orthobiologics; surgeon’s willingness to continue to use the Company’s NanoMetalene products; the Company’s ability to attract new, high-quality distributors based on its NanoMetalene surface technology; the Company’s reliance on a sole provider to apply NanoMetalene surface technology to its products; the Company’s ability to continue to invest in medical education and training; general economic and business conditions in the markets in which the Company does business, both in the U.S. and abroad; and other risks and uncertainties more fully described in the Company’s news releases and periodic filings with the Securities and Exchange Commission. The Company’s public filings with the Securities and Exchange Commission are available at www.sec.gov.
You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date when made. SeaSpine does not intend to revise or update any forward-looking statement set forth in this news release to reflect events or circumstances arising after the date hereof, except as may be required by law.
Investor Relations Contact